OXBDF (Oxford BioMedica) Long-Term Debt: $55.5 Mil (As of Dec. 2025)


OXBDF Oxford BioMedica PLC OXBDF
71 GF Score
Price $7.93
GF Value $6.84
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is Oxford BioMedica Long-Term Debt?

Oxford BioMedica OXBDF 71 Long-Term Debt is $55.5 Mil as of Dec. 2025. GuruFocus rates OXBDF with a GF Score™ of 71/100 and a GF Value™ of $6.84 (Modestly Overvalued). The stock has 5 warning signs investors should review.

Oxford BioMedica's Long-Term Debt for the quarter that ended in Dec. 2025 was $55.5 Mil.

Oxford BioMedica's quarterly Long-Term Debt declined from Dec. 2024 ($50.3 Mil) to Jun. 2025 ($50.0 Mil) but then increased from Jun. 2025 ($50.0 Mil) to Dec. 2025 ($55.5 Mil).

Oxford BioMedica's annual Long-Term Debt increased from Dec. 2023 ($48.8 Mil) to Dec. 2024 ($50.3 Mil) and increased from Dec. 2024 ($50.3 Mil) to Dec. 2025 ($55.5 Mil).

Oxford BioMedica  (OTCPK:OXBDF) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Oxford BioMedica Long-Term Debt Related Terms

Oxford BioMedica Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Oxford BioMedica's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oxford BioMedica Long-Term Debt Chart

Oxford BioMedica Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 48.45 48.78 50.30 55.54

Oxford BioMedica Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 48.78 49.85 50.30 49.95 55.54
OXBDF
71GF Score
Oxford BioMedica PLC OXBDF
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of $55.5 Mil mean?
Oxford BioMedica (OXBDF) has a Long-Term Debt of $55.5 Mil as of Dec. 2025.
Is Oxford BioMedica's Long-Term Debt too high?
Oxford BioMedica's current Long-Term Debt is $55.5 Mil. Overall, Oxford BioMedica has a GF Score™ of 71/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Oxford BioMedica's Long-Term Debt compare to VRTX and REGN?
Oxford BioMedica's Long-Term Debt of $55.5 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Biotechnology company?
A good Long-Term Debt depends on the Biotechnology industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Oxford BioMedica's current Long-Term Debt is $55.5 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oxford BioMedica stock overvalued right now?
Based on GuruFocus' analysis, Oxford BioMedica (OXBDF) is currently considered Modestly Overvalued. The stock's GF Value™ is $6.84, compared to a current price of $7.93 — trading 15.9% above its estimated fair value. The current Long-Term Debt is $55.5 Mil. Oxford BioMedica's overall GF Score™ is 71/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Oxford BioMedica (OXBDF), the current Long-Term Debt is $55.5 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Oxford BioMedica (OXBDF) Overvalued in 2026?

Based on GuruFocus' analysis, Oxford BioMedica stock appears to be overvalued. The current stock price of $7.93 is trading 15.9% above its estimated GF Value™ of $6.84. GuruFocus considers Oxford BioMedica to be Modestly Overvalued.

Key valuation signals for OXBDF:

  • Long-Term Debt: $55.5 Mil
  • GF Value™: $6.84 vs. price of $7.93 (15.9% above fair value)
  • GF Score™: 71/100 with 5 warning signs

No single metric tells the full story. See the OXBDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Oxford BioMedica Business Description

Other Exchanges OXBl:UKOXB:UKOXO:Germany
Address Transport Way, Windrush Court, Oxford, GBR, OX4 6LT
Oxford BioMedica PLC is a contract development and manufacturing organization (CDMO) focused on cell and gene therapy. The company specializes in viral vector development and manufacturing for cell and gene therapy, with expertise in lentivirus, adeno-associated virus (AAV), adenovirus, and other viral vector types. Geographically, it derives maximum revenue from the United States, and the rest from Europe, the UK, and the Rest of the world.
71GF Score

Get the complete analysis for OXBDF

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.93
Price
$6.84
GF Value